TICKERNERD
Menu
ALCALCHealthcare · Medical Instruments & Supplies

ALC Stock Forecast: Alcon AG Price Predictions for 2026-2027

Last close, 3 Sept 2026
$72
−0.22% on the day

The 26 Wall Street analysts covering Alcon AG hold a median 12-month price target of $86 — +19.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 70 of 100 as at 2 Sept 2026 — in the upper half. Here, the model and the Street point the same way.

Market cap
$34.8B
Ticker Nerd rank
70 / 100
Median analyst target
$86
Analysts covering
26
Revenue$2.7B+9.4% y/y
Operating income$292.0M
Net income$189.0M
Free cash flow$227.0M
Quarterly, 8 quarters to 31 Mar 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−0.2%
1M
+2.7%
YTD
−8.1%
1Y
−8.0%
From 52W high
−16.9%
From 52W low
+16.2%
$62
$87
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ALC stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Alcon AG on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 2 Sept 2026
70 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
97
Value
88
Accruals
75
Issuance
73
Revisions
67
Quality
65
Growth
52
Momentum
26
Size
7

Volatility (97): The share price has been relatively steady.

Momentum (26): The shares have been drifting down relative to others.

Size (7): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ALC stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ALC, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$60$70$80$90$100$110Oct 25Jan 26Apr 26Jul 26ALCHigh $103Median $86Low $62

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says26 analysts
20 Buy5 Hold1 Sell
Low $62Median $86High $103

The green dot is the last close — the median target sits +19.3% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
12 Aug 2026JP MorganMaintainsNeutral$78 → $78
12 Aug 2026MizuhoMaintainsOutperform$80 → $85
11 Aug 2026BTIGReiteratesBuy$82
11 Aug 2026NeedhamMaintainsBuy$95 → $98
15 July 2026MizuhoMaintainsOutperform—
15 July 2026MizuhoMaintainsOutperform$85 → $80
8 May 2026BarclaysMaintainsEqual-Weight—
7 May 2026BairdMaintainsOutperform—
7 May 2026MizuhoMaintainsOutperform—
7 May 2026Wells FargoMaintainsOverweight—
6 May 2026BTIGMaintainsBuy—
6 May 2026NeedhamMaintainsBuy—
23 Mar 2026BTIGReiteratesBuy—
9 Mar 2026StifelMaintainsHold—
26 Feb 2026BarclaysMaintainsEqual-Weight—
26 Feb 2026NeedhamMaintainsBuy—
26 Feb 2026Wells FargoUpgradeOverweight—
25 Feb 2026BTIGMaintainsBuy—
9 Jan 2026StifelDowngradeHold—
11 Dec 2025B of A SecuritiesDowngradeUnderperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ALC appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ALC vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 3 Sept 2026, Alcon AG returned −8.0% against +21.4% for the S&P 500, dividends included.

ALC vs S&P 500, last 12 monthsTotal return, rebased to 100
8090100110120Oct 25Jan 26Apr 26Jul 26ALCS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ALC analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+1.0%
Analysts raising
2
Analysts cutting
5
Fundamentals

Alcon AG (ALC) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
55.4×

Cheaper than 13% of US stocks

Price / sales
3.2×

Cheaper than 39% of US stocks

Price / book
1.6×

Cheaper than 54% of US stocks

EV / EBITDA
16.1×

Cheaper than 21% of US stocks

Growth & margins
Revenue growth (YoY)
8.7%

Higher than 49% of US stocks

Earnings growth (YoY)
−100.0%

Higher than 1% of US stocks

Gross margin
56.4%

Higher than 69% of US stocks

Operating margin
14.6%

Higher than 72% of US stocks

Net margin
5.9%

Higher than 62% of US stocks

Returns & dividend
Return on equity
2.9%

Higher than 50% of US stocks

Return on assets
2.8%

Higher than 64% of US stocks

Dividend yield
2.0%

Higher than 45% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Alcon AG (ALC) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Alcon AG has a market value of $34.8B and an enterprise value of $38.7B.

  • Revenue in the twelve months to 31 Mar 2026: $10.6B. The latest quarter grew 8.7% year on year.

  • Net income over the same four quarters: $819.0M, a 7.7% net margin.

  • Diluted earnings per share, trailing twelve months: $1.66.

  • Free cash flow in the twelve months to 31 Mar 2026: $1.6B, after $571.0M of capital spending.

  • Alcon AG spent $751.0M on share buybacks in the twelve months to 31 Mar 2026.

  • Shares outstanding: 487.7M.

  • Trailing P/E: 55.4×; forward P/E: 18.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 1.99%, paying out 27% of earnings.

  • Alcon AG employs 25,000 people — $425K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 4 Sept 2026

Data provided by Twelve Data

Peers

ALC vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Instruments & Supplies
CompanyMarket capTKN rank
ALCAlcon AG$34.8B
70
RMDResMed, Inc.$33.7B
71
MDLNMedline, Inc.$47.7B
19
BDXBecton, Dickinson & Co.$51.7B
93
WSTWest Pharmaceutical Services, Inc.$24.6B
94
SOLVSolventum Corp.$15.9B
92
COOThe Cooper Cos., Inc.$13.7B
81

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Alcon AG — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ALC news & analysis

Alcon: A Re-Rating In Eyesight

Seeking Alpha · 3 Sept 2026positive

Seeking Alpha describes Alcon as a structurally advantaged ophthalmology leader with a durable equipment-to-consumables model and strong recurring revenue streams. The article notes the stock trades at about 18x forward earnings, with management targeting 25% core operating margin by FY2027 and raising core EPS growth guidance to 12–15%.

Why it matters — ALC watchers would care because the piece highlights the company's raised EPS guidance, margin-expansion targets, and capital-return program, all of which point to a potentially re-rated growth story.

Alcon Launches UNITY M, a Premium Ophthalmic Microscope Delivering Precise Control

Business Wire · 3 Sept 2026positive

Alcon announced the launch of UNITY M, a premium ophthalmic microscope designed to deliver precise control, according to a Business Wire release.

Why it matters — A new premium product launch reflects Alcon's continued investment in expanding and refreshing its ophthalmic surgical equipment portfolio.

Alcon Prices EUR 500 Million Senior Notes Offering

Business Wire · 26 Aug 2026neutral

Alcon announced it has priced a EUR 500 million senior notes offering. The announcement was made from Geneva via Business Wire.

Why it matters — The senior notes offering represents a significant capital markets move for Alcon, which ALC watchers would track as a funding and financing development.

Alcon: A Strong Company Trading Close To Its Intrinsic Value, Buy

Seeking Alpha · 17 Aug 2026positive

Alcon reported strong core operating profit, up 17% excluding a one-time non-cash $402 million charge, and raised its full-year 2026 profit forecast for the second consecutive quarter. A discounted cash flow valuation indicates the stock is trading close to its intrinsic value.

Why it matters — Alcon watchers would note the company's continued strengthening of its profitability outlook, as it upgraded its 2026 profit forecast for the second straight quarter.

Bill Ackman once exited Netflix stake in a huff. Why he's buying the streaming giant again as well as these five stocks.

Market Watch · 13 Aug 2026neutral

Bill Ackman's Pershing Square added Netflix and five other stocks to its portfolio in the last six months, after previously exiting a stake in the streaming giant.

Why it matters — As a major consumer and entertainment industry investor, Ackman's portfolio moves can signal shifting sector trends that may indirectly impact Alcon's market dynamics.

FAQ

Frequently asked questions about ALC stock

What is the ALC stock price forecast for 2026-2027?

The 26 Wall Street analysts covering Alcon AG have a median 12-month price target of $86, with estimates ranging from $62 to $103. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ALC stock a buy right now?

Of the 26 analysts covering Alcon AG, 20 rate it a Buy, 5 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Alcon AG 70 out of 100 across roughly 4,600 US stocks as at 2 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ALC?

As at 2 Sept 2026, Alcon AG ranks 70 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (97 of 100).

Will ALC stock go up?

No one can know that. What the data says: the median 12-month target from 26 analysts implies +19.3% from the last close, and Ticker Nerd's factor model ranks Alcon AG 70 out of 100 as at 2 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ALC stock forecast for 2030?

No analyst covering Alcon AG publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ALC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $62 to $103 over the next 12 months.

How has ALC stock performed over the past year?

Alcon AG returned -8.0% over the 12 months to 3 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Alcon AG do?

Alcon Inc. is a global eye care company focused on products and technologies that support vision health across surgical and everyday care settings.

What is the latest news on ALC?

The most recent item we track (Seeking Alpha, 3 Sept 2026): "Alcon: A Re-Rating In Eyesight". Seeking Alpha describes Alcon as a structurally advantaged ophthalmology leader with a durable equipment-to-consumables model and strong recurring revenue streams. The article notes the stock trades at about 18x forward earnings, with management targeting 25% core operating margin by FY2027 and raising core EPS growth guidance to 12–15%.

Company

About Alcon AG.

Alcon Inc. is a global eye care company focused on products and technologies that support vision health across surgical and everyday care settings. Alcon Inc. develops, manufactures, and markets a broad portfolio for cataract surgery, vitreoretinal procedures, glaucoma care, refractive surgery, contact lenses, lens care, and other ocular health needs. Its Surgical business provides implantable products, surgical equipment, diagnostics, and consumables used by ophthalmologists in hospitals and specialty clinics. Its Vision Care business includes daily disposable and reusable contact lenses, color-enhancing lenses, and a range of eye health products for dry eye, allergies, glaucoma support, contact lens care, and redness relief. Headquartered in Geneva, Switzerland, Alcon Inc. serves eye care professionals, medical institutions, and consumers in markets worldwide as a leading provider in ophthalmology and vision care.

CEO Mr. David J. Endicott · 25,000 employees · Switzerland · https://www.alcon.com